<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>839</ReferenceId>
        <DateLastUpdated>2019-06-04-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12406196</PubmedId>
            <Abstract>In Schistosoma mansoni infection, CD4 T cells specific for parasite egg antigens mediate perioval granuloma formation in the liver and intestines. Mice of the CBA strain develop a severe form of disease and a significant proportion of their CD4 T cell response is directed against the major egg antigen Sm-p40 and its immunodominant T cell epitope peptide 234-246. Here, we show that intranasal (i.n.) treatment of infected CBA mice with a fusion protein of the cholera toxin B subunit (CTB) with peptide 234-246 (CTB::pep) results in significant down-modulation of hepatic granulomatous inflammation and fibrosis. Moreover, egg antigen-stimulated dispersed hepatic granuloma cells, as well as mesenteric lymph node CD4 T cells from the CTB::pep-treated mice, produced significantly more transforming growth factor (TGF)-beta than that produced by treated or untreated controls. The data demonstrate that i.n. administration of a single immunodominant peptide conjugated to CTB can lead to down-regulation of the hepatic immunopathology associated with schistosomiasis, and that this down-regulation is, at least in part, mediated by TGF-beta.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>423-7</ArticlePages>
            <ArticleTitle>Diminished immunopathology in Schistosoma mansoni infection following intranasal administration of cholera toxin B-immunodominant peptide conjugate correlates with enhanced transforming growth factor-beta production by CD4 T cells.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hernandez</LastName>
                    <ForeName>Hector J</ForeName>
                </Author>
                <Author>
                    <LastName>Rutitzky</LastName>
                    <ForeName>Laura I</ForeName>
                </Author>
                <Author>
                    <LastName>Lebens</LastName>
                    <ForeName>Mike</ForeName>
                </Author>
                <Author>
                    <LastName>Holmgren</LastName>
                    <ForeName>Jan</ForeName>
                </Author>
                <Author>
                    <LastName>Stadecker</LastName>
                    <ForeName>Miguel J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Pathology, Tufts University School of Medicine, Boston, MA 02111, USA. miguel.stadecker@tufts.edu.</Affiliations>
            <ArticleChemicalList>Antigens, Helminth;Helminth Proteins;Immunodominant Epitopes;Peptide Fragments;Transforming Growth Factor beta;cholera toxin B-immunodominant peptide conjugate (234-246);p40 egg antigen, Schistosoma;Cholera Toxin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Administration, Intranasal; Animals; Antigens, Helminth(administration &amp; dosage; immunology); CD4-Positive T-Lymphocytes(immunology; metabolism); Cholera Toxin(administration &amp; dosage; immunology); Granuloma(immunology); Helminth Proteins; Immunodominant Epitopes(chemistry; immunology); Mice; Mice, Inbred CBA; Peptide Fragments(administration &amp; dosage; immunology); Schistosoma mansoni(immunology; pathogenicity); Schistosomiasis mansoni(immunology; microbiology; pathology); Snails; Transforming Growth Factor beta(biosynthesis)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>24</Volume>
                <Issue>8</Issue>
                <Title>Parasite immunology</Title>
                <Issn>1365-3024</Issn>
                <MedlineTa>Parasite Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Sm-p40 peptide</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PKSDNQIKAVPAS</LinearSequence>
                        <StartingPosition>234</StartingPosition>
                        <EndingPosition>246</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12812.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000385</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>48146</EpitopeId>
                <ReferenceStartingPosition>234</ReferenceStartingPosition>
                <ReferenceEndingPosition>246</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This is the immunodominant epitope of Sm-p40 antigen. The natural epitope was linked to cholera toxin B subunit. The epitope sequence was defined by a reference given in the article. The epitope was linked to cholera toxin B subunit in all assays.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B and table 1</LocationOfData>
                        <TCellId>9090</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000236</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:1395</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000385</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Schistosoma mansoni</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope linked to cholera toxin B subunit was administered intranasally (5 weekly doses) starting one week after infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>121</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -T cell subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Schistosomal egg antigen (SEA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P12812.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000385</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>196</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope coupled with cholera toxin B subunit was adminisitered intranasally (5 weekly doses) 1 week after infection and resulted in increased TGF-beta production compared to mice who received either Cholera toxin alone or PBS. A marginal reduction in IFNg, IL-4, IL-5, and IL-10 production was also seen, but these values were not significantly different from the animals treated with cholera toxin alone.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A and table 1</LocationOfData>
                        <TCellId>9175</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000236</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:1395</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000385</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Schistosoma mansoni</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The epitope linked to cholera toxin B subunit was administered intranasally (5 weekly doses) starting one week after infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Schistosomal egg antigen (SEA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P12812.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10000385</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>196</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope coupled with cholera toxin B subunit was adminisitered intranasally (5 weekly doses) 1 week after infection and resulted in increased TGF-beta production by granuloma cells taken from liver compared to mice who received  PBS.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>10155</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000236</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PKSDNQIKAVPAS</LinearSequence>
                                            <StartingPosition>234</StartingPosition>
                                            <EndingPosition>246</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P12812.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000385</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope linked to cholera toxin B subunit was administered intranasally (5 weekly doses) starting one week after infection.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>schistosoma mansoni</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000385</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope coupled with cholera toxin B subunit was adminisitered intranasally (5 weekly doses) 1 week after infection and resulted in decreased hepatic granuloma size and hepatic fibrosis compared to mice who received PBS.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

